Underground Peptide Biohacking Expands in SF Tech Circles
Primary reporting plus FDA notices, Wired biohacking history and Nature Biotechnology pipeline analysis reveal SF peptide self-experimentation trends, associated regulatory and health risks, and connections to prior rationalist-driven enhancement cycles.
Lede: San Francisco tech professionals are increasingly self-experimenting with Chinese-sourced peptides including semaglutide, tirzepatide and retatrutide at private events, according to direct attendee reporting (12gramsofcarbon.com, 2024).
The primary account describes a spring peptide-themed party where multiple founders discussed injecting compounds for weight loss, skin rejuvenation and personality changes, with one exchange confirming concurrent use of tirzepatide and retatrutide; this continues Scott Alexander’s January 2024 Astral Codex Ten reference to similar Bay Area peptide use at house parties (astralcodexten.substack.com, 2024). Related coverage in Wired on Silicon Valley biohackers documents parallel nootropics and longevity self-experimentation waves dating to the 2010s, linking the practices to rationalist communities (wired.com/story/inside-the-silicon-valley-longevity-cult, 2023).
Mainstream reporting omitted scale: four founders at one event were actively building peptide companies, reflecting a shift from AI discussions now viewed as generic; FDA notices from 2023-2024 document adverse events tied to compounded or research-grade peptides purchased online, including microbial contamination risks (fda.gov/news-events, 2024). A Nature Biotechnology review cites accelerating peptide therapeutic pipelines, noting AI-enabled design is lowering barriers for novel analogs that biohackers access pre-approval (nature.com/articles/s41587-023-01968-7, 2023).
Patterns indicate regulatory tightening is likely, mirroring 2010s nootropics crackdowns and recent semaglutide shortage enforcement; health data from off-label GLP-1 use shows both metabolic benefits and emerging questions on long-term muscle and neurological impacts, with longevity implications still unproven in healthy-user cohorts.
AXIOM: Peptide self-experimentation in SF tech will trigger targeted FDA enforcement on gray-market Chinese suppliers within 18 months while accelerating legitimate AI-designed peptide pipelines for longevity indications.
Sources (3)
- [1]Notes from the SF Peptide Scene(https://12gramsofcarbon.com/p/notes-from-the-sf-peptide-scene)
- [2]FDA Warns on Compounded Semaglutide and Peptides(https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-warns-consumers-about-compounded-semaglutide)
- [3]Peptide Therapeutics Review(https://www.nature.com/articles/s41587-023-01968-7)